Psilocybin and Epilepsy: Risks and Considerations

Psilocybin and Epilepsy: Risks and Considerations

Epilepsy and psilocybin occupy a complicated intersection. Psilocybin is excluded from most clinical trials by protocols that list seizure disorder as a contraindication — not because of strong evidence of harm, but because of theoretical risk, liability concerns, and the absence of safety data in this population. Yet people with epilepsy do use psilocybin, and some of them — including those seeking relief from treatment-resistant mood disorders common in epilepsy — have compelling reasons to want access to information.

This guide presents the current state of knowledge, which is limited, and the considerations that matter for anyone with epilepsy thinking carefully about this question.

The Epilepsy-Psychiatric Comorbidity Problem

People with epilepsy have significantly elevated rates of:

• Depression (25-35% of epilepsy patients)
• Anxiety disorders (20-25%)
• Treatment-resistant forms of both, partly because many standard medications interact with antiepileptic drugs (AEDs)
• Post-traumatic stress from seizure experiences

This creates a painful situation: the population with some of the strongest reasons to seek alternative treatments is excluded from the clinical trials that are advancing those treatments.

What Is Known About Psilocybin and Seizures

The Pharmacological Concern

Psilocybin primarily acts on 5-HT2A serotonin receptors. This receptor subtype is expressed in neurons throughout the brain including cortical pyramidal cells — the cell type most involved in generating seizures.

5-HT2A activation can, in theory:

• Reduce inhibitory GABAergic tone
• Increase glutamatergic (excitatory) activity
• Alter cortical excitability in ways that could, in some contexts, lower seizure threshold

Whether this pharmacological concern translates into actual seizure risk in humans is not well established. The existing evidence is limited and mixed.

Case Reports and Survey Data

There are no published prospective studies of psilocybin in people with epilepsy. The available evidence consists of:

Case reports suggesting risk: Scattered case reports of seizures occurring in temporal proximity to psilocybin use. In most cases, confounds (concomitant stimulant use, sleep deprivation, other substances) make attribution unclear.

Survey data suggesting low incidence: Survey studies of psychedelic users with self-reported epilepsy have found no dramatically elevated seizure frequency compared to baseline, though methodological limitations are significant (selection bias — people who had bad outcomes may not participate in surveys).

Anecdotal reports of therapeutic benefit: Multiple first-person accounts from people with epilepsy who use psilocybin report no adverse seizure effects and subjective benefit for comorbid mood symptoms. These are not evidence of safety but suggest catastrophic outcomes are not universal.

The Seizure Threshold Problem

Seizure threshold — how much neurological provocation is needed to trigger a seizure — varies between individuals and within an individual over time. Factors that lower seizure threshold include sleep deprivation, stress, hyperventilation, alcohol withdrawal, fever, and some medications.

The set and setting conditions surrounding typical psilocybin sessions include factors that could be either protective or provocative: reduced stress (potentially protective), altered sleep patterns (potentially provocative), intense emotional experience (unknown effect), altered breathing patterns (potentially provocative).

Epilepsy Types and Risk Stratification

Not all epilepsy carries identical risk, and risk stratification matters:

Higher Concern Epilepsy Types

Temporal lobe epilepsy (TLE): The most common focal epilepsy. TLE involves hyperexcitability in the temporal cortex and limbic system — regions intensely engaged during psilocybin sessions. The interaction is unknown but warrants special caution.

Photosensitive epilepsy: Visual phenomena during psilocybin sessions, including rapidly changing patterns, could potentially trigger seizures in people with photosensitive epilepsy. This is a specific theoretical concern.

Seizures with known triggers: If seizures have identified triggers (stress, sleep deprivation, specific stimuli), and if session conditions approach those triggers, risk may be higher.

Lower Concern Contexts

Seizure-free periods: Someone with epilepsy who has been fully seizure-free for multiple years on stable medication has a lower profile than someone with frequent breakthrough seizures.

Well-controlled epilepsy: Epilepsy fully controlled by medication, with no breakthrough seizures, and without the high-risk subtypes above is meaningfully different from poorly controlled epilepsy.

Antiepiliptic Drug Interactions

This is another dimension of the problem. AEDs have complex pharmacology, and many affect serotonergic systems:

Lamotrigine: Commonly used for epilepsy and bipolar disorder. Some evidence suggests lamotrigine reduces LSD and possibly psilocybin effects through effects on voltage-gated sodium channels and glutamate modulation. The interaction is not dangerous but may reduce therapeutic efficacy.

Valproate: Broad-spectrum AED with multiple mechanisms. Limited information on psilocybin interaction. The serotonergic effects of valproate could theoretically alter psilocybin's effects.

Levetiracetam: Mechanism distinct from most AEDs (SV2A binding). Less known interaction with serotonergic systems. Perhaps the AED with fewest theoretical interaction concerns.

Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital): These drugs strongly induce CYP enzymes that metabolize many substances. Effects on psilocybin metabolism are not well characterized.

Practical Harm Reduction for People with Epilepsy

Given that people with epilepsy will make their own decisions, harm reduction principles apply:

Medical consultation: Essential — not necessarily for permission (which many physicians will not give), but to understand seizure risk, medication interactions, and to ensure any session is not done in secret from one's treating neurologist.

Seizure control status: A session during a period of active, poorly controlled seizures is a different risk profile than a session during a prolonged seizure-free period.

Setting safety: Seizure safety precautions in the session setting: nothing to fall against, water nearby, sitter briefed on seizure response (do not restrain, time the seizure, call emergency services if it exceeds 5 minutes or is immediately followed by another).

Avoid additional risk factors: Sleep deprivation, alcohol, and other factors that lower seizure threshold should be avoided before and during the session.

Start low: If proceeding, lower doses reduce both intensity and potential neurological demands.

Know your emergency resources: The sitter should know the person has epilepsy and what to do in the event of a seizure.

A Note on Desperation and Risk Tolerance

People with treatment-resistant depression or anxiety superimposed on epilepsy sometimes describe feeling that their quality of life is already severely impaired — that the risks of inaction are as real as the risks of psilocybin. This is not an irrational position, and it deserves acknowledgment.

The honest answer is: the seizure risk from psilocybin in epilepsy is real but poorly quantified; it is not certainly prohibitive; individual risk varies substantially; and informed, careful harm reduction can lower but not eliminate that risk.

Anyone in this position deserves accurate information rather than categorical dismissal — and is best served by the expansion of research that would actually answer these questions.